Karolinska Development divests 4,6 million shares in portfolio company OssDsign
STOCKHOLM, SWEDEN, December 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests 4,6 million shares in the portfolio company OssDsign and thereby strengthens the investment company’s liquidity. Karolinska Development holds nearly 5 million shares in OssDisgn after the divestment.
The divestment is being carried out in two stages, as the acquirer, Linc AB, following the transaction, will exceed (directly and indirectly) 10 percent of the voting rights in OssDsign. On December 10, 2024, 4.4 million shares were sold through a direct sale to Linc AB, while the sale of an additional 200,000 shares is conditional upon approval from the Inspectorate for Strategic Products under the Act (2023:560) on the Review of Foreign Direct Investments. The divestment provides Karolinska Development with a total capital infusion of approximately SEK 40 million.
Karolinska Development is a long-term owner of OssDsign and was involved in the listing of OssDsign on Nasdaq First North Growth Market in Stockholm in 2019. After the divestment, Karolinska holds close to 5 million shares in OssDsign.
After the divestment of 4.6 million shares, Karolinska Development’s ownership in OssDsign amount to approximately 5 percent.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.
Attachment
